Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06647251

Comparison of 3 RF Delivery Modes of the QDOT Catheter for Paroxymal Atrial Fibrillation (AF) Ablation

Pulmonary vein isolation is the main treatment of paroxysmal and persistent atrial fibrillation.

The aim of our study is to prospectively compare the efficacy and safety of the 3 options of radiofrequency delivery with QDOT Micro™, with systematic use of catheter stabilization tools and tighter lesions

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Institut Mutualiste Montsouris

Paris, 75014, France

Location status: Recruiting

Location contact

Frederic SEBAG

CONTACT

[email protected]

+33156616263

About this study

Pulmonary vein isolation (PVI) is the main treatment of paroxysmal and persistant atrial fibrillation.

PVI is achieved by point-by-point radiofrequency ablation that creates flexible lesion set within targeted area.

PVI using standard ablation catheter with limited power (50W) have been described in case series with favorable efficacy and safety.

QDOTMicro™ is a radiofrequency ablation catheter that incorporates advanced, high-energy ablation, improved temperature monitoring, optimized irrigation, and higher signal resolution.

QDOT Micro™ provides several options regarding radiofrequency administration :

  • Q-MODE : provides high power short duration (HPSD) unitl 50W radiofrequency,
  • Q-MODE+ : provides very high power very short duration (vHSPD) until 90W radiofrequency,
  • Hybrid Q-MODE/Q-MODE+ : is a combination of two methods. In our experience, stability is a prerequisite for PVI with QDOT Micro™.

Small series have described encouraging results (85% isolation, unpublished data) with stabilization tools such as low-volume ventilation or apnea, high-rate simualtion, Vizigo bi-directional sheath (Vizigo™).

Recently, preliminary animal data argue in favor or reducing the interpoint distance with QDOT™.

To date, there is no study comparing the 3 options of radiofrequency delivery. The aim of our study is to prospectively compare the efficacity and safety of the 3 options of radiofrequency delivery with QDOT Micro™, with systematic use of catheter stabilization tools and tighter lesions.

The same device is used in all three randomisation groups. The difference between the intervention is the intensity of the radiofrequency applied.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient aged 18 or over
  • First atrial fibrillation ablation
  • Paroxysmal atrial fibillation defined as atrial fibrillation lasting less than 48 hours
  • Early atrial fibrillation defined as atrial fibrillation lastiing between 7 days and 3 months
  • At least one episode of atrial fibrillation in the year preceding study entry
  • Patient affiliated to a health insurance

Exclusion criteria

  • History of atrial fibrillation ablation (surgery or catheter)
  • Documented left atrial thrombus
  • Left atrial (LA) diameter > 60mm / LA area > 35cm2 / Left atrial volulme index (LAVI) > 45ml/m2
  • N/STEMI replacement or angioplasty or valve within 3 months prior to registration
  • Any contraindication mentioned in the instructions for use of the QDOT MICRO™ bidirectional navigation catheter
  • Patient unable to understand study information
  • Patient deprived of liberty by judicial or administrative decision

Treatment and study plan

Q-MODE : radiofrequency ablation up to 50W

Procedure

The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.

For patient randomized in this arm, the device is set to Q-MODE option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 50W.

Q-MODE+ : radiofrequency up to 90W

Procedure

The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.

For patient randomized in this arm, the device is set to Q-MODE+ option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 90W.

Hybride Q-MODE/Q-MODE+: radiofrequency ablation up to 50W in the anterior part, and 90W in the posterior part

Procedure

The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.

For patient randomized in this arm, the device is set to "Q-MODE/Q-MODE+" option: the intensity of radiofrequency delivered to isolate the pulmonary vein is limited to 50W in the anterior part and to 90W in the posterior part.

Primary outcomes

  1. Incidence of primary adverse events related to the ablation procedure

    Time frame: 7 days after ablation

    Incidence of primary adverse events within 7 days after ablation in the 3 arms

  2. Acute procedural success

    Time frame: At the end of the ablation procedure

    Acute procedural success is defined as electrical isolation of all pulmonary veins

Secondary outcomes

  1. Incidence of serious adverse event

    Time frame: within 7 days (early onset), 7 to 30 days (periprocedural), up to 18 months (late onset) of the ablation procedure

    Incidence of serious adverse events

  2. Rate of additional lesions

    Time frame: At the end of the ablation procedure

    Rate of additional lesions between all targeted veins and per subject

  3. Location of additional lesions

    Time frame: At the end of the ablation procedure

    Anatomical location of additional lesions

  4. Use of another catheter

    Time frame: At the end of the ablation procedure

    Use of another catheter than QDOT in all targeted veins

  5. Time spent in operating room

    Time frame: At the end of the ablation procedure

    Time spent in operating room

  6. Skin-to-skin time

    Time frame: At the end of the ablation procedure

    Skin-to-skin time

  7. Glove-to-glove time

    Time frame: At the end of the ablation procedure

    Glove-to-glove time = total procedure time

  8. Mapping time

    Time frame: At the end of the ablation procedure

    Mapping time

  9. Total ablation time

    Time frame: At the end of the ablation procedure

    Total ablation time

  10. Left vein ablation time

    Time frame: At the end of the ablation procedure

    Left vein ablation time

  11. Right vein ablation time

    Time frame: At the end of the ablation procedure

    Right vein ablation time

  12. Number of radiofrequency applications

    Time frame: At the end of the ablation procedure

    Number of radiofrequency applications

  13. Number of vHPSD radiofrequency applications

    Time frame: At the end of the ablation procedure

    Number of vHPSD (very High Power Short Duration) radiofrequency applications

  14. Number of HPSD radiofrequency applications

    Time frame: At the end of the ablation procedure

    Number of HPSD (High Power Short Duration) radiofrequency applications

  15. Temperature

    Time frame: At the end of the ablation procedure

    Temperature

  16. Power

    Time frame: At the end of the ablation procedure

    Power

  17. Contact force

    Time frame: At the end of the ablation procedure

    Contact force

  18. Impedance

    Time frame: At the end of the ablation procedure

    Impedance

Study contacts

Contact information is provided by the study sponsor or research team.

Naly ANDRIAMBAO

CONTACT

[email protected]

+33156616439

Sponsors and collaborators

Lead sponsor

Institut Mutualiste Montsouris

Other

Registry information

Official study title

Comparison of 3 RF Delivery Modes of the QDOT Catheter for Paroxymal AF Ablation: a Prospective Study

Acronym: QDOT

Important dates

Study start
2024
Primary completion
2027
Study completion
2028
First posted
Oct 17, 2024
Registry last updated
Oct 17, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.